Clinical Trial

GV101 in Healthy Obese Participants

Completed Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this trial is to evaluate the efficacy and safety of GV101 for weight loss over a range of doses in participants with obesity. The primary efficacy endpoint is the mean percent change in body weight from baseline at Week 16 in each treated group as compared with placebo.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2025-05-13; most recent amendment 2026-02-03.
Status change: Active, Not Recruiting → Completed 2026-02-03
Status change: Recruiting → Active, Not Recruiting 2025-10-09
Status change: Not Yet Recruiting → Recruiting 2025-06-30
Trial Details
NCT Number NCT06979505
Lead Sponsor Graviton Bioscience Corporation
Conditions Weight Management
Enrollment 131 participants
Start Date 2025-06-30
Primary Completion 2026-01-28 (estimated)
Study Completion 2026-01-28 (estimated)
Updated on ClinicalTrials.gov 2026-02-04